Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aortic Source of Brain Embolism.

Geoffrey A. Donnan1, Stephen M. Davis, Elizabeth F. Jones

  • 1National Stroke Research Institute, Austin & Repatriation Medical Centre, 300 Waterdale Road, West Heidelberg, Victoria 3081, Australia. gdonnan@unimelb.edu.au

Current Treatment Options in Cardiovascular Medicine
|June 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of dual antiplatelet treatment up to 72 hours after mild ischemic stroke or transient ischemic attack in patients with established cardiovascular disease.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics·2026
Same author

Dual Antiplatelet Therapy and Immediate Intensive Statin in Mild Ischemic Stroke: A Randomized Trial.

Neurology·2026
Same author

Predictors of Hematoma Expansion and Response to Andexanet in Patients With Intracerebral Hemorrhage: Secondary Analyses of the ANNEXA-I Randomized Clinical Trial.

Stroke·2026
Same author

Asundexian for Secondary Stroke Prevention.

The New England journal of medicine·2026
Same author

Prognostic Factors for Long-Term Risk of Stroke After Transient Ischemic Attack or Minor Stroke: A Systematic Review and Meta-Analysis.

Circulation·2026
Same author

Association between free fatty acid and 3-month prognosis of acute ischemic stroke.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2026

Aortic arch atheroma, plaque in the aorta, is a significant risk factor for ischemic stroke. Thicker atheromas (≥4 mm) sharply increase stroke risk, necessitating further research into optimal secondary prevention strategies.

Area of Science:

  • Cardiovascular Medicine
  • Neurology
  • Vascular Surgery

Background:

  • Aortic arch atheroma is increasingly recognized as an independent risk factor for ischemic stroke.
  • The association is supported by autopsy and in vivo studies, with stroke risk correlating with atheroma thickness.

Purpose of the Study:

  • To highlight the clinical significance of aortic arch atheroma as a stroke risk factor.
  • To discuss diagnostic methods and current uncertainties in clinical management, particularly secondary prevention.
  • To introduce the Aortic arch Related Cerebral Hazard (ARCH) trial investigating optimal secondary prevention.

Main Methods:

  • Diagnosis of aortic arch atheroma is typically achieved through transesophageal echocardiography, with MRI and CT as alternative imaging modalities.

Related Experiment Videos

  • Clinical suspicion arises in cases of transient ischemic attack or ischemic stroke without identified cardiac or arterial sources.
  • The ARCH trial is a prospective study designed to compare the efficacy of different secondary prevention strategies.

    • Main Results:

    • A sharp increase in stroke risk is observed for aortic arch atheroma thickness of 4 mm or greater.
    • Current management options include antiplatelet agents, anticoagulants, and less commonly, thrombolysis or surgery.
    • Aggressive risk factor control (blood pressure, lipids, diabetes) is a general management principle.

    Conclusions:

    • Aortic arch atheroma is a critical, actionable risk factor for ischemic stroke.
    • Further research, including the ARCH trial, is crucial to establish optimal secondary prevention strategies.
    • Comprehensive risk factor management remains a cornerstone of care for patients with aortic arch atheroma.